Status:

WITHDRAWN

Relationship Between Circulating Tumor Cell Cultures' Treatment Response and Clinical Outcomes

Lead Sponsor:

UNC Lineberger Comprehensive Cancer Center

Conditions:

Cancer

Metastasis Lung

Eligibility:

All Genders

18+ years

Brief Summary

The purpose of this prospective, non-randomized, single-center pilot exploratory study is to investigate whether established circulating tumor cell (CTC) cultures have a similar response to targeted t...

Detailed Description

This study will isolate circulating tumor cells (CTCs) from blood samples taken from patients with liver and/or lung metastases who will receive systemic treatments. The CTCs will be cultured and give...

Eligibility Criteria

Inclusion

  • Patients with a metastatic solid tumor malignancy with either liver and/or lung metastasis. Patients with newly diagnosed metastatic disease who have not had systemic therapy or are progressing on systemic therapy fitting one of the following cohorts:
  • Patients had a tumor or liquid biopsy with molecular analysis (genomic analysis or other type of molecular characterization) resulting in a therapeutic target with planned targeted therapy by the patient's treating physician.
  • Gastric cancer patients who have failed the first and second line chemotherapy.
  • Bladder cancer patients (with liver and/or lung metastasis) who will receive systemic treatment.
  • Scheduled to initiate systemic treatment for management of their disease. The systemic treatment will be either cytotoxic chemotherapy or targeted therapy but not checkpoint inhibitor immunotherapy.
  • ≥18 years of age
  • Written informed consent obtained and signed
  • Able to have blood collection without excessive difficulty

Exclusion

  • Patient unwilling or unable to complete informed consent
  • Currently pregnant or lactating women
  • Physical or psychological inability to complete sample collection for any reason including but not limited to: inability to tolerate any study procedures, any physical limitation that would undermine the safety of the subject in the study, or any psychiatric or neurological condition that inhibits full comprehension of study requirements and inability to complete informed consent, as determined by treating physician

Key Trial Info

Start Date :

June 1 2021

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

June 1 2023

Estimated Enrollment :

Patients enrolled

Trial Details

Trial ID

NCT04280640

Start Date

June 1 2021

End Date

June 1 2023

Last Update

October 18 2021

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.